Mastodawn

Eli Lilly posted a Q4 earnings beat as demand for its obesity drugs Zepbound and Mounjaro soared, driving revenue up 43% and sending shares up 9% in pre-market trading.
#YonhapInfomax #EliLilly #ObesityDrugs #Q4Earnings #RevenueGrowth #SharePriceSurge #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103893

Eli Lilly Delivers Q4 Earnings Surprise on Obesity Drug Demand—Shares Surge 9%

Eli Lilly posted a Q4 earnings beat as demand for its obesity drugs Zepbound and Mounjaro soared, driving revenue up 43% and sending shares up 9% in pre-market trading.

Yonhap Infomax